Drugs / [124I]IB PF 06687234
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03414788 | Dec 2020 → Feb 2022 | inflammatory bowel disease | Pfizer | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [124I]IB PF 06687234 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03414788 ↗ |
| Route | Intravenous | “single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously” NCT03414788 ↗ |